NCT02583425终止2 期
Pilot Study of DFN-11 Injection in Medication Overuse Headache
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- The Number of Headache Hours in the Baseline Period (28 Days of Subjects Using Their Usual Medication for Headaches) and in the Treatment Period (28 Days of Subjects Using DFN-11 for Headaches)
研究概览
简要总结
Efficacy and Safety Pilot Study of DFN-11 Injection in Medication Overuse Headache
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of medication overuse headache within the past year in the following categories
- •Diagnosis of migraine, with or without aura for at least 12 months
- •Experience an average of > 10 headache days per month for the past 12 months
- •Females must:
- •i. be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and willing to continue throughout the study, or ii. be surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or iii. be postmenopausal (spontaneous amenorrhea for at least 1 year)
- •Females of child-bearing potential must have a negative urine pregnancy test at all visits.
- •Able and willing to read and comprehend written instructions and complete the electronic diary.
- •Must have internet access to complete daily headache diary.
排除标准
- •Current use of medication for headache/migraine prophylaxis that has not been stable for 30 days prior to screening. Stable is defined as no recent dosing change within 30 days of screening.
- •Hemiplegic or basilar migraine
- •History, symptoms or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes
- •Uncontrolled hypertension (screening systolic/diastolic blood pressure > 140/90 mmHg in 2 out of 3 readings)
- •Clinically significant hepatic impairment
- •History of epilepsy or conditions associated, which in the opinion of the Investigator, increase the likelihood of present day seizure
- •History (within 2 years) of drug or alcohol abuse as defined by DSM-IV-TR criteria
- •Systemic disease, which in the opinion of the Investigator, would contraindicate participation
- •History of a neurological or psychiatric condition, which in the opinion of the Investigator would contraindicate participation
- •Pregnant or lactating women
- •Have taken any investigational medication within 30 days before screening, or are scheduled to receive an investigational drug
- •Subjects with a positive urine drug screen for recreational drugs or marijuana (whether legal or not) or for prescription drugs not explained by stated concomitant medications
- •Clinical laboratory or electrocardiogram (ECG) abnormality that in the opinion of the Investigator would endanger the subject or interfere with the study conduct. If the results of the clinical laboratory or ECG are outside of normal reference range the subject may still be enrolled but only if these findings are determined to be not clinically significant by the Investigator. This determination must be recorded in the subject's source document prior to enrolment.
- •Fridericia's corrected QT (QTcF) interval greater than 450 msec
- •Severe renal impairment (creatinine > 2 mg/dl)
- •Serum total bilirubin > 2.0 mg/dL
- •Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal
- •Subjects with uncontrolled diabetes mellitus, or a glycosylated hemoglobin (HbA1c) > 7.0%, or with diabetes mellitus requiring insulin
- •Subjects who in the opinion of the investigator experience rebound headache from caffeine usage
研究组 & 干预措施
DFN-11
Experimental
DFN-11 Injection upon occurrence of migraine
干预措施: DFN-11 Injection (Drug)
结局指标
主要结局
The Number of Headache Hours in the Baseline Period (28 Days of Subjects Using Their Usual Medication for Headaches) and in the Treatment Period (28 Days of Subjects Using DFN-11 for Headaches)
时间窗: 28 days Baseline period and 28 days of Treatment period (Total 56 days)
次要结局
- The Number of Acute Headache Medication Doses in the Baseline Period (28 Days of Subjects Using Their Usual Medication for Headaches) and in the Treatment Period (28 Days of Subjects Using DFN-11 for Headaches)(28 days Baseline period and 28 days of Treatment period (Total 56 days))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating MigraineRapidly Escalating MigraineNCT02571049Dr. Reddy's Laboratories Limited24
已完成
3 期
DFN-11 Injection in Episodic Migraine With or Without AuraEpisodic MigraineNCT02569853Dr. Reddy's Laboratories Limited268
已完成
1 期
Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)Macular DegenerationNCT00109499GenVec
已完成
1 期
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)TumorsNCT00248404Kiadis Pharma155
招募中
3 期
GD-11 for Injection in the Treatment of Acute Ischemic StrokeAcute Ischemic StrokeNCT06299579Beijing Tiantan Hospital980